{"product_id":"cd19-car-t-cell-therapy-for-autoimmune-diseases-a-15-patient-case-series","title":"CD19 CAR T-Cell Therapy for Autoimmune Diseases: A 15-Patient Case Series","description":"\u003cp\u003eIn a small case series of 15 patients with three severe autoimmune diseases, a single infusion of CD19 CAR T-cell therapy allowed every patient to stop immunosuppressive medications, with remission in all patients with systemic lupus erythematosus, a major clinical response in all patients with idiopathic inflammatory myositis, and reduced disease activity in all patients with systemic sclerosis. All 8 patients with systemic lupus erythematosus (SLE) achieved remission, all 3 patients with idiopathic inflammatory myositis had a major clinical response, and all 4 patients with systemic sclerosis had reduced disease activity. All 15 patients stopped taking immunosuppressive medications, and side effects were mostly mild. The authors conclude that this treatment appears feasible, safe, and effective, and that larger controlled trials are now needed.\u003c\/p\u003e\n\n\u003ch1\u003eCD19 CAR T-Cell Therapy for Autoimmune Diseases: A 15-Patient Case Series\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#whatiscar\"\u003eWhat Is CAR T-Cell Therapy?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#patients\"\u003eWho Were the Patients?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#manufacturing\"\u003eHow the CAR T-Cells Were Made\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#expansion\"\u003eCAR T-Cell Expansion and B-Cell Depletion\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#efficacy\"\u003eKey Findings: Treatment Effectiveness\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#lupus\"\u003eResults in Systemic Lupus Erythematosus\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#myositis\"\u003eResults in Idiopathic Inflammatory Myositis\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#sclerosis\"\u003eResults in Systemic Sclerosis\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#autoantibodies\"\u003eAutoantibody and Vaccine Responses\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#bcells\"\u003eB-Cell Recovery After Treatment\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Study\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Next Steps\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a 15-patient case series, a single infusion of CD19 CAR T-cell therapy allowed all patients to stop immunosuppressive medications, with remission in the patients with SLE, a major clinical response in the patients with myositis, and reduced disease activity in the patients with systemic sclerosis.\u003c\/li\u003e\n\u003cli\u003eAll 8 patients with SLE achieved remission, all 3 with myositis had a major response, and all 4 with systemic sclerosis had reduced disease activity.\u003c\/li\u003e\n\u003cli\u003eSide effects were mostly mild: grade 1 cytokine release syndrome in 10 patients, one grade 2, and one grade 1 neurotoxicity; no severe cases occurred.\u003c\/li\u003e\n\u003cli\u003eThe immune system's ability to fight infections was largely preserved, and patients could still respond to new vaccinations after treatment.\u003c\/li\u003e\n\u003cli\u003eThis was a small, uncontrolled case series; larger controlled trials with longer follow-up are needed to confirm effectiveness and safety.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eAutoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis are chronic conditions. In these diseases, the immune system mistakenly attacks the body's own tissues. This leads to ongoing inflammation, organ damage, and increased risk of death.\u003c\/p\u003e\n\n\u003cp\u003eCurrent treatments for these diseases rely on long-term immune suppression. These drugs can control symptoms, but they rarely cure the disease. Patients often must take them for years or even for life. Achieving lasting remission without drugs has remained an elusive goal.\u003c\/p\u003e\n\n\u003cp\u003eB cells are a type of immune cell that normally produce antibodies to fight infections. In autoimmune diseases, however, autoreactive B cells (B cells that attack the body's own tissues) drive the disease process. Previous treatments targeting B cells used antibodies. These antibodies either depleted B cells by binding to a surface molecule called CD20, or they blocked B-cell activation by targeting a protein called B-cell activating factor.\u003c\/p\u003e\n\n\u003cp\u003eAntibody-based B-cell targeting improved treatment for some patients. However, it did not achieve long-lasting, drug-free remission. This is where CAR T-cell therapy comes in. CAR T cells can potentially achieve deep depletion of B cells by targeting CD19, a molecule found on a wide range of B cells and plasmablasts (a type of antibody-producing cell).\u003c\/p\u003e\n\n\u003cp\u003eOver the past two years, several individual case reports and one small case series suggested that CD19 CAR T-cell therapy might be feasible and effective in autoimmune disease. This new study presents data on both short-term and long-term effectiveness and safety in 15 patients with severe forms of three different autoimmune diseases.\u003c\/p\u003e\n\n\u003ch2 id=\"whatiscar\"\u003eWhat Is CAR T-Cell Therapy?\u003c\/h2\u003e\n\n\u003cp\u003eChimeric antigen receptor (CAR) T-cell therapy is a treatment in which a patient's own T cells (a type of immune cell) are genetically modified. The modification gives the T cells a new receptor called a chimeric antigen receptor. This receptor allows the T cells to recognize and attack specific target cells.\u003c\/p\u003e\n\n\u003cp\u003eCAR T-cell therapy has become a powerful tool for treating cancer, particularly blood cancers. Targeting malignant B cells with CAR T cells has greatly improved treatment for certain lymphomas and leukemias. The same approach can be applied to autoimmune diseases, because autoreactive B cells cause damage in these conditions.\u003c\/p\u003e\n\n\u003cp\u003eThe treatment works by deeply depleting B cells. The CAR T cells target CD19, a surface molecule expressed on a broad spectrum of B cells and plasmablasts. By eliminating these cells, the treatment aims to \"reset\" the immune system and stop the autoimmune attack.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis study was a case series conducted at multiple centers in Germany. The researchers evaluated 15 patients with severe autoimmune diseases. The patients received a single infusion of CD19 CAR T cells.\u003c\/p\u003e\n\n\u003cp\u003eBefore receiving the CAR T cells, each patient underwent preconditioning chemotherapy. This preconditioning used two drugs: fludarabine and cyclophosphamide. The purpose of this chemotherapy is to make space in the immune system for the new CAR T cells to grow and function.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers assessed how well the treatment worked for up to 2 years after the infusion. They used several standardized measurement tools:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFor SLE:\u003c\/strong\u003e The Definition of Remission in SLE (DORIS) remission criteria, the Lupus Low Disease Activity State (LLDAS) criteria, and the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). The SLEDAI-2K score ranges from 0 to 105, with higher scores indicating greater disease activity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFor idiopathic inflammatory myositis:\u003c\/strong\u003e The American College of Rheumatology–European League against Rheumatism (ACR–EULAR) Total Improvement Score. This score ranges from 0 to 100. A score of 0 to 19 means no clinical response, 20 to 39 means a minimal response, 40 to 59 means a moderate response, and 60 to 100 means a major clinical response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFor systemic sclerosis:\u003c\/strong\u003e The European Scleroderma Trials and Research Group (EUSTAR) activity index. This score ranges from 0 to 10, with higher scores indicating greater disease activity. The modified Rodnan skin score was also used. This score ranges from 0 to 51, with higher scores indicating worse skin fibrosis (scarring and thickening of the skin).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSafety was carefully monitored. Patients were screened daily for cytokine release syndrome (a potentially serious immune reaction). Patients were also screened daily for immune effector cell–associated neurotoxicity syndrome (ICANS, which involves neurological symptoms). Screening occurred during the first 10 days after the CAR T-cell infusion. These conditions were assessed using the American Society for Transplantation and Cellular Therapy consensus criteria.\u003c\/p\u003e\n\n\u003cp\u003eMyelotoxicity (damage to bone marrow) was defined as grade III or IV neutropenia (low levels of a type of white blood cell). Myelotoxicity was also defined as leukocytopenia (low white blood cell count). The neutropenia or leukocytopenia had to last more than 28 days after therapy. The researchers also monitored CAR T-cell levels, leukocyte subsets, autoantibodies, vaccination-related antibodies, and B-cell populations.\u003c\/p\u003e\n\n\u003cp\u003eThe study was offered through an expanded-access program for critically ill patients in Germany. All patients provided written informed consent. The study followed CARE guidelines for case reports and the principles of the Declaration of Helsinki.\u003c\/p\u003e\n\n\u003ch2 id=\"patients\"\u003eWho Were the Patients?\u003c\/h2\u003e\n\n\u003cp\u003eFrom February 2021 through May 2023, a total of 15 patients were treated. The group included 8 patients with SLE, 3 with idiopathic inflammatory myositis, and 4 with systemic sclerosis.\u003c\/p\u003e\n\n\u003cp\u003eAll patients had severe, progressive disease. They had all failed to respond adequately to at least two different standard immunosuppressive treatments. The median number of previous treatments was 5, with a range of 2 to 14.\u003c\/p\u003e\n\n\u003cp\u003eThe patients with SLE had active disease. Their median SLEDAI-2K score was 13 (interquartile range, 9.3 to 16). Interquartile range means the middle 50% of values fell between these two numbers. Each SLE patient had at least one severe (A) score on the British Isles Lupus Assessment Group (BILAG) 2004 index. All had histologically proven glomerulonephritis (kidney inflammation) of World Health Organization grade III or IV.\u003c\/p\u003e\n\n\u003cp\u003eAll patients with idiopathic inflammatory myositis and systemic sclerosis had interstitial lung disease (scarring of lung tissue). Their lung function was reduced. The median forced vital capacity (a measure of how much air the lungs can hold) was 53% in the myositis group (interquartile range, 49 to 64). The median forced vital capacity was 36% in the sclerosis group (interquartile range, 24 to 53). The median diffusing capacity of the lungs for carbon monoxide was 67% in the myositis group. This measure shows how well oxygen moves from the lungs into the blood, and the interquartile range was 49 to 75. The median diffusing capacity of the lungs for carbon monoxide was 59% in the sclerosis group (interquartile range, 34 to 72).\u003c\/p\u003e\n\n\u003cp\u003ePatients with idiopathic inflammatory myositis showed active muscle involvement. Their median creatine kinase level (a marker of muscle damage) was 4298 U per liter (interquartile range, 766 to 9305). Patients with systemic sclerosis had active skin involvement. Their median modified Rodnan skin score was 25.5 (interquartile range, 18.8 to 30.8).\u003c\/p\u003e\n\n\u003cp\u003eEight patients had previously received B-cell–depleting agents. Nine patients had previously received cyclophosphamide, with a median dose of 3 g (interquartile range, 1 to 6; mean ±SD, 5.3±6.9 g).\u003c\/p\u003e\n\n\u003cp\u003eSome patients had been previously reported in earlier publications. These included Patients 1 through 5 with SLE, Patients 1 and 2 with idiopathic inflammatory myositis, and Patient 1 with systemic sclerosis.\u003c\/p\u003e\n\n\u003ch2 id=\"manufacturing\"\u003eHow the CAR T-Cells Were Made\u003c\/h2\u003e\n\n\u003cp\u003eThe investigational medicinal product used in this study was called MB-CART19.1. It consisted of the patient's own CD19 CAR–transduced CD4- and CD8-enriched T cells. These cells were derived from a leukapheresis product (a sample of blood cells collected from the patient). The cells were processed using a device called the CliniMACS Prodigy (made by Miltenyi Biotec).\u003c\/p\u003e\n\n\u003cp\u003eThe manufacturing process was highly consistent among the 15 patients. Cell proliferation during manufacturing, transduction efficacy (how efficiently the CAR gene was inserted into the T cells), and the cellular composition of each product were all similar across patients.\u003c\/p\u003e\n\n\u003cp\u003eIn all 15 patients, more than 1×10⁹ (1 billion) CD19 CAR T cells could be produced. Transduction efficiencies ranged from 18% to 44%. Most CD19 CAR T-cell products contained a higher number of CD4+ cells than CD8+ T cells. The exceptions were the product for Patient 8 with SLE and the products for Patients 1 and 4 with systemic sclerosis.\u003c\/p\u003e\n\n\u003ch2 id=\"expansion\"\u003eCAR T-Cell Expansion and B-Cell Depletion\u003c\/h2\u003e\n\n\u003cp\u003eAfter infusion, the CAR T cells rapidly multiplied in the body. They reached peak concentrations after a mean of 8.6±0.8 days (median, 9 days; interquartile range, 9 to 9). At the peak of expansion, the median number of circulating CAR T cells was 146 per microliter (interquartile range, 61 to 697).\u003c\/p\u003e\n\n\u003cp\u003eCD19+ B cells were rapidly eliminated from the peripheral blood. This happened after a mean of 5.9±2.2 days (median, 7 days; interquartile range, 3 to 7).\u003c\/p\u003e\n\n\u003cp\u003eIn 14 of the 15 patients, B cells reappeared after a mean of 112±47 days (median, 100 days; interquartile range, 72 to 153). The last patient (Patient 4 with systemic sclerosis, with 128 days of follow-up) was still waiting for B-cell recovery at the time of the analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers found that patients previously exposed to B-cell–depleting antibodies had lower B-cell counts at baseline. These patients also had a longer period of B-cell aplasia (absence of B cells). The median B-cell aplasia time was 138 days (interquartile range, 66 to 189) in patients previously exposed to B-cell–depleting antibodies. This compared with 86 days (interquartile range, 70 to 124) in patients who had not been exposed to these antibodies.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, the peak of CAR T-cell expansion was lower in patients who had previously received rituximab (a B-cell–depleting drug) than in those who had not. The median peak was 91 cells per microliter (interquartile range, 38 to 270) in the rituximab-treated group. This compared with 461 cells per microliter (interquartile range, 61 to 1275) in the group that had not received rituximab.\u003c\/p\u003e\n\n\u003cp\u003eThe duration of CAR T-cell presence in the blood was also shorter in patients who had previously received rituximab. The median duration was 40 days (interquartile range, 30 to 61) in the rituximab group. This compared with 58 days (interquartile range, 26 to 79) in the group that had not received rituximab.\u003c\/p\u003e\n\n\u003ch2 id=\"efficacy\"\u003eKey Findings: Treatment Effectiveness\u003c\/h2\u003e\n\n\u003cp\u003eThe median follow-up was 15 months, with a range of 4 to 29 months. The results were striking across all three diseases.\u003c\/p\u003e\n\n\u003cp\u003eAll 15 patients successfully discontinued glucocorticoids (steroid medications) and all other immunosuppressive medications by the final follow-up. This means every patient achieved drug-free status.\u003c\/p\u003e\n\n\u003cp\u003eThe following sections describe the specific results for each disease group.\u003c\/p\u003e\n\n\u003ch2 id=\"lupus\"\u003eResults in Systemic Lupus Erythematosus\u003c\/h2\u003e\n\n\u003cp\u003eAll eight patients with SLE met LLDAS criteria and achieved DORIS remission after 6 months. Their SLEDAI-2K score was zero after 6 months. A SLEDAI-2K score of zero means no measurable disease activity.\u003c\/p\u003e\n\n\u003cp\u003eAnalysis of BILAG status showed resolution of SLE in all major disease categories after 6 months. Long-term follow-up of up to 29 months showed that SLE disease activity remained absent in all eight patients. Their SLEDAI-2K score remained at zero.\u003c\/p\u003e\n\n\u003cp\u003eAdditional improvements were seen in laboratory markers:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAnti-dsDNA antibodies (antibodies that attack the body's own DNA) disappeared and remained negative.\u003c\/li\u003e\n\u003cli\u003eComplement factor C3 levels (a protein involved in immune function) normalized.\u003c\/li\u003e\n\u003cli\u003eProteinuria (protein in the urine, a sign of kidney damage) disappeared during the entire observation period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne patient (Patient 4 with SLE) had a rebound of proteinuria 4 months after CAR T-cell therapy. A follow-up kidney biopsy did not reveal any signs of lupus nephritis. Instead, the biopsy showed concomitant podocytopathy (a condition affecting the kidney's filtering cells). This patient did not have a relapse and had only very mild proteinuria at the last follow-up (24 months).\u003c\/p\u003e\n\n\u003ch2 id=\"myositis\"\u003eResults in Idiopathic Inflammatory Myositis\u003c\/h2\u003e\n\n\u003cp\u003eAll three patients with idiopathic inflammatory myositis had an ACR–EULAR major clinical response after 3 months. They also had normalization of creatine kinase levels. These responses were maintained over time.\u003c\/p\u003e\n\n\u003cp\u003eMuscular function, as measured by the Manual Muscle Test–8 (MMT-8), normalized in all three patients. The MMT-8 score ranges from 0 to 150, with lower scores indicating weaker muscles. Extramuscular disease activity (disease activity outside the muscles) also ceased.\u003c\/p\u003e\n\n\u003ch2 id=\"sclerosis\"\u003eResults in Systemic Sclerosis\u003c\/h2\u003e\n\n\u003cp\u003eIn the four patients with systemic sclerosis, global disease activity decreased in all four. Global disease activity was measured by the EUSTAR activity index. Skin activity, measured by the modified Rodnan skin score, also decreased in all four patients.\u003c\/p\u003e\n\n\u003cp\u003eIn the three patients with at least 6 months of follow-up, the median change in the EUSTAR activity index was −4.2 points (interquartile range, −4.7 to −2.3). The median change in the modified Rodnan skin score was −9 points (interquartile range, −17 to −7). Negative numbers indicate improvement.\u003c\/p\u003e\n\n\u003ch2 id=\"autoantibodies\"\u003eAutoantibody and Vaccine Responses\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers analyzed autoantibodies (antibodies that attack the body's own tissues) in detail. In patients with SLE, autoantibodies against several targets disappeared. These targets included double-stranded DNA, single-stranded DNA, secondary necrotic cells, nucleosomes, and Smith protein.\u003c\/p\u003e\n\n\u003cp\u003eLong-term analysis of autoantibodies in patients with SLE who had at least 1 year of follow-up (seven of eight patients) confirmed a sustained absence of SLE-specific autoantibodies.\u003c\/p\u003e\n\n\u003cp\u003eProtective IgG responses to standard vaccines remained stable. These vaccines included tetanus, measles, mumps, rubella, varicella–zoster virus (the virus that causes chickenpox and shingles), and Epstein–Barr virus. This means the patients' ability to fight these infections was preserved.\u003c\/p\u003e\n\n\u003cp\u003eModerate decreases, but not loss, of antibodies against pneumococci (bacteria that can cause pneumonia) and SARS-CoV-2 (the virus that causes COVID-19) were noted during long-term observation.\u003c\/p\u003e\n\n\u003cp\u003eVaccinations given after CD19 CAR T-cell therapy and B-cell recovery led to a subsequent increase in antigen-specific IgG levels. These vaccinations included SARS-CoV-2 (in two patients), pneumococcus (in one patient), and tetanus (in two patients). This shows that the immune system could still respond to new vaccines after treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"bcells\"\u003eB-Cell Recovery After Treatment\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers analyzed B-cell subsets at baseline, 4 months, and 12 months after CAR T-cell therapy. When B cells reappeared, they showed a naive B-cell phenotype. Naive B cells are immature B cells that have not yet encountered an antigen. This suggests the immune system was rebuilding itself from scratch.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, CD19+CD27+ memory B cells (B cells that remember past encounters with pathogens or self-tissues) were drastically reduced. There was a limited increase in these memory B cells between 4 and 12 months. This increase was predominantly seen in preswitched IgD+ CD27+ B cells.\u003c\/p\u003e\n\n\u003cp\u003eCD27+CD38+ plasmablasts and SLE-associated activated CD11c+ memory B cells were not found after B-cell reconstitution. Immature CD38+ B cells, which indicate that B cells are being newly produced by the bone marrow, increased at 4 months and decreased thereafter.\u003c\/p\u003e\n\n\u003cp\u003eThese findings suggest that the treatment \"reset\" the B-cell compartment. The new B cells that emerged were primarily naive cells, not the autoreactive memory cells that drive autoimmune disease.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eThe safety profile was generally favorable. The most common side effect was cytokine release syndrome (CRS), a condition in which the immune system releases large amounts of inflammatory chemicals. Grade 1 CRS occurred in 10 patients. Grade 1 is the mildest form.\u003c\/p\u003e\n\n\u003cp\u003eOne patient had grade 2 cytokine release syndrome. One patient had grade 1 immune effector cell–associated neurotoxicity syndrome (ICANS). One patient developed pneumonia that required hospitalization.\u003c\/p\u003e\n\n\u003cp\u003eNo cases of severe (grade 3 or higher) cytokine release syndrome or ICANS were reported.\u003c\/p\u003e\n\n\u003cp\u003eThe mean duration of B-cell aplasia (absence of B cells) was 112±47 days. This period of B-cell absence is expected with this treatment and is part of how it works.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides encouraging evidence that CD19 CAR T-cell therapy may offer a new treatment option for patients with severe autoimmune diseases. The most significant finding is that all 15 patients were able to stop all immunosuppressive medications. This is remarkable because these patients had severe, treatment-resistant disease before the therapy.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with SLE, the treatment led to complete remission in all eight cases. Their disease activity scores dropped to zero, and their autoantibodies disappeared. For patients with idiopathic inflammatory myositis, muscle function normalized and disease activity stopped. For patients with systemic sclerosis, skin and global disease activity decreased.\u003c\/p\u003e\n\n\u003cp\u003eThe safety profile was also encouraging. Most side effects were mild. The cytokine release syndrome and neurotoxicity that can occur with CAR T-cell therapy were mostly low-grade and manageable.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the immune system's ability to fight infections was largely preserved. Protective antibodies from previous vaccinations remained stable. Patients could still respond to new vaccinations after treatment.\u003c\/p\u003e\n\n\u003cp\u003eHowever, patients should understand that this is a case series, not a randomized controlled trial. Case series describe what happened in a small group of patients. They cannot prove that the treatment caused the improvements, because there was no comparison group. Larger, controlled trials are needed to confirm these results.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Study\u003c\/h2\u003e\n\n\u003cp\u003eThis study has several important limitations that patients and clinicians should consider.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSmall sample size:\u003c\/strong\u003e Only 15 patients were treated. This is too few to draw definitive conclusions about effectiveness or safety.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo control group:\u003c\/strong\u003e All patients received the treatment. There was no comparison group receiving a placebo or standard treatment. This makes it difficult to know how much of the improvement was due to the treatment versus other factors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShort follow-up for some patients:\u003c\/strong\u003e The median follow-up was 15 months, with a range of 4 to 29 months. Longer follow-up is needed to determine whether remissions are sustained.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCase series design:\u003c\/strong\u003e Case series are observational. They cannot establish cause and effect.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSingle-arm study:\u003c\/strong\u003e Without a comparison group, the researchers cannot calculate how much better this treatment is than existing options.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialized treatment centers:\u003c\/strong\u003e The treatment was offered through an expanded-access program at specialized centers in Germany. Results may differ in other settings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors note that the preliminary short-term effects in some of these patients were previously reported. This means some data may overlap with earlier publications.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Next Steps\u003c\/h2\u003e\n\n\u003cp\u003eThe authors conclude that CD19 CAR T-cell transfer appeared to be feasible, safe, and effective in three different autoimmune diseases. They state that these results provide rationale for further controlled clinical trials.\u003c\/p\u003e\n\n\u003cp\u003eBased on this study, the following next steps are recommended:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eConduct randomized controlled trials:\u003c\/strong\u003e Larger studies with control groups are needed to confirm the effectiveness of CD19 CAR T-cell therapy in autoimmune diseases.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtend follow-up:\u003c\/strong\u003e Longer observation periods are needed to determine whether drug-free remission is sustained over many years.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStudy different patient populations:\u003c\/strong\u003e Future research should include patients with less severe disease and from different geographic regions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompare with standard treatments:\u003c\/strong\u003e Head-to-head comparisons with existing therapies will help determine where CAR T-cell therapy fits in the treatment landscape.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonitor long-term safety:\u003c\/strong\u003e Continued monitoring is needed to detect any delayed side effects or complications.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eFor patients with severe autoimmune diseases who have not responded to standard treatments, this study offers hope. However, CAR T-cell therapy is not yet approved for autoimmune diseases. It remains an investigational treatment available only through clinical trials or expanded-access programs.\u003c\/p\u003e\n\n\u003cp\u003ePatients interested in this treatment should discuss it with their rheumatologist or immunologist. They should ask about eligibility for clinical trials and the potential risks and benefits.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is CD19 CAR T-cell therapy?\u003c\/h3\u003e\n\u003cp\u003eIt is a treatment where a patient's own T cells are genetically modified to recognize and attack cells that carry a marker called CD19. This marker is found on a wide range of B cells and plasmablasts. By deeply depleting these cells, the treatment aims to reset the immune system and stop the autoimmune attack.\u003c\/p\u003e\n\u003ch3\u003eWho might be eligible for this treatment?\u003c\/h3\u003e\n\u003cp\u003eIn the reported case series, patients had severe, progressive autoimmune disease and had failed at least two standard immunosuppressive treatments. The median number of prior treatments was five. The therapy was offered through an expanded-access program for critically ill patients. It is not yet approved for autoimmune diseases and is available only through clinical trials or expanded-access programs.\u003c\/p\u003e\n\u003ch3\u003eWhat were the results for lupus (SLE) in this case series?\u003c\/h3\u003e\n\u003cp\u003eAll eight patients with SLE achieved remission and met low disease activity criteria after six months. Their disease activity scores dropped to zero. Anti-dsDNA antibodies disappeared and remained negative. Proteinuria disappeared during the observation period. These results were maintained for up to 29 months in follow-up.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects occurred with CD19 CAR T-cell therapy?\u003c\/h3\u003e\n\u003cp\u003eThe most common side effect was cytokine release syndrome (CRS). Grade 1 CRS occurred in 10 patients, and one patient had grade 2. One patient had grade 1 neurotoxicity (ICANS). One patient developed pneumonia requiring hospitalization. No severe CRS or ICANS occurred. B-cell absence lasted a mean of 112 days.\u003c\/p\u003e\n\u003ch3\u003eHow long did patients go without immunosuppressive drugs?\u003c\/h3\u003e\n\u003cp\u003eAll 15 patients successfully discontinued glucocorticoids and all other immunosuppressive medications by the final follow-up. This means every patient achieved drug-free status. The median follow-up was 15 months, with a range of 4 to 29 months. Longer follow-up is needed to determine whether these drug-free remissions are sustained over many years.\u003c\/p\u003e\n\u003ch3\u003eWhat does a SLEDAI-2K score of zero mean?\u003c\/h3\u003e\n\u003cp\u003eThe SLEDAI-2K score measures lupus disease activity, ranging from 0 to 105, with higher scores indicating greater activity. A score of zero means no measurable disease activity. In the case series, all eight patients with SLE had a SLEDAI-2K score of zero after six months, and this remained at zero during long-term follow-up.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this case series?\u003c\/h3\u003e\n\u003cp\u003eThis was a small case series of 15 patients with no control group, so it cannot prove that the treatment caused the improvements. Follow-up was short for some patients (median 15 months). The treatment was given at specialized centers in Germany. Larger, controlled trials are needed to confirm the results and assess long-term safety.\u003c\/p\u003e\n\u003ch3\u003eI have severe lupus that hasn't responded to multiple treatments — when should I seek a second opinion about CAR T-cell therapy?\u003c\/h3\u003e\n\u003cp\u003eWhen standard immunosuppressive drugs have failed to control severe, progressive disease, a second opinion can clarify whether an investigational option such as CD19 CAR T-cell therapy is appropriate. In a 15-patient case series, all eight patients with SLE achieved drug-free remission, with disease activity scores falling to zero and autoantibodies disappearing, though this remains an investigational treatment available only through clinical trials or expanded-access programs. A second opinion can help confirm eligibility, review prior treatments, and weigh potential risks and benefits. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e CD19 CAR T-Cell Therapy in Autoimmune Disease  A Case Series with Follow-up NEJM 2024\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Fabian Müller, M.D., Jule Taubmann, M.D., Laura Bucci, M.D., Artur Wilhelm, Ph.D., Christina Bergmann, M.D., Simon Völkl, Ph.D., Michael Aigner, Ph.D., Tobias Rothe, Ph.D., Ioanna Minopoulou, M.D., Carlo Tur, M.D., Johannes Knitza, M.D., Soraya Kharboutli, M.D., Sascha Kretschmann, Ph.D., Ingrid Vasova, M.D., Silvia Spoerl, M.D., Hannah Reimann, Ph.D., Luis Munoz, M.D., Roman G. Gerlach, Ph.D., Simon Schäfer, Ph.D., Ricardo Grieshaber-Bouyer, M.D., Anne-Sophie Korganow, M.D., Dominique Farge-Bancel, M.D., Dimitrios Mougiakakos, M.D., Aline Bozec, Ph.D., Thomas Winkler, Ph.D., Gerhard Krönke, M.D., Andreas Mackensen, M.D., and Georg Schett, M.D.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e The New England Journal of Medicine, February 22, 2024, Volume 390, Number 8, pages 687-700\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1056\/NEJMoa2308917\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e Deutsche Forschungsgemeinschaft and others\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes only and should not replace consultation with a qualified healthcare provider. Patients should discuss any treatment decisions with their medical team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47919009661084,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-cd19-car-t-cell-therapy-for-autoimmune-diseases-a-15-patient-case-series-hero.png?v=1793341296","url":"https:\/\/diagnosticdetectives.com\/ar\/products\/cd19-car-t-cell-therapy-for-autoimmune-diseases-a-15-patient-case-series","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}